Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Trade Lower Premarket Wednesday

10/06/2021 | 09:12am EST


ę MT Newswires 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
11/24Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment ..
AQ
11/24FDA Approves Takeda Drug Livtencity for Post-Transplant CMV Infection
MT
11/24Takeda Gets US FDA Nod on Treatment for Cytomegalovirus
MT
11/23U.S. FDA approves Takeda's drug for post-transplant CMV infection
RE
11/23Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment ..
BU
11/23Takeda?s LIVTENCITYTM Approves by U.S. FDA as the First and Only Treatment for People A..
CI
11/23TAKEDA PHARMACEUTICAL : LIVTENCITY (maribavir) Approved by U.S. FDA as the First and Only ..
PU
11/23U.S. FDA approves Takeda's drug for post-transplant infection
RE
11/22Kamada Shares Up After Buying Portfolio From Saol Therapeutics
DJ
11/17Denali Says Takeda to Co-Develop, Co-Commercialize DNL593 Frontotemporal Dementia Inves..
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 407 B 30 070 M 30 070 M
Net income 2022 223 B 1 964 M 1 964 M
Net Debt 2022 3 334 B 29 426 M 29 426 M
P/E ratio 2022 21,9x
Yield 2022 5,74%
Capitalization 4 932 B 43 512 M 43 528 M
EV / Sales 2022 2,43x
EV / Sales 2023 2,29x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 136,00 JPY
Average target price 4 322,86 JPY
Spread / Average Target 37,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-16.48%43 512
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049